Viemed Healthcare earnings date
Want to see VMD full AI Analyst Report?
Viemed Healthcare (VMD) Q3 2026 Earnings Report
VMD Q3 2026 EPS Results
- Actual EPS
- $0.11
- Consensus EPS
- $0.12
- Beat/Miss
- Missed by -$0.01
- One Year Ago EPS
- $0.09
VMD Q3 2026 Revenue Results
- Actual Revenue
- $80.67M
- Expected Revenue
- $80.78M
- Beat/Miss
- Missed by -$107.00K
- YoY Revenue Growth
- +12.18%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Viemed Healthcare's next earnings date is estimated for March 10, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was broadly positive, led by record revenue, double-digit organic growth, strong net income and adjusted EBITDA expansion, growing sleep and maternal health volumes, improving ventilation revenue, capital returns, and higher revenue guidance. The primary challenges were slightly lower gross margin, increased audit-related work and payment timing, temporarily weaker cash conversion, volatility in ventilation active patients, and a lower upper end to adjusted EBITDA guidance.
Management now expects full-year revenue of $316 million to $320 million, compared with the previous range of $314 million to $320 million; adjusted EBITDA guidance is $64 million to $66 million, compared with the previous range of $64 million to $68 million; and net CapEx is expected to be 8% to 9% of revenue, compared with 8.5% to 10% previously. The revised outlook anticipates sequential growth in both revenue and adjusted EBITDA in the fourth quarter and excludes any potential future acquisitions or strategic transactions. Viemed is on track to enter 2 additional states per quarter beginning in the fourth quarter for maternal health, expects ventilator active patient count to be back up in the fourth quarter, and expects to stay up in the 20-plus percent adjusted EBITDA for the time being.
- Record Revenue and Strong Net Income GrowthThird-quarter revenue reached a record $80.7 million, up 12.2% year over year. Net income attributable to Viemed increased 32% year over year to $4.6 million, or $0.11 per diluted share, and rose approximately 68% from the second quarter.
- Organic Growth Beyond the Lehan AcquisitionFor the first time since the Lehan acquisition, both the current and prior-year quarters included a full three months of Lehan operations. Management said the 12.2% revenue increase therefore reflected expansion across existing businesses rather than incremental revenue from an acquisition.
- Sleep Therapy Patient GrowthViemed served 43.9 thousand therapy patients during the quarter, more than 6 thousand above the second quarter and 37.5% above a year ago. PAP setups increased sequentially and year over year, reflecting growth both in patients receiving therapy and in activity bringing patients into care.
- Resupply Expansion and Process ImprovementsThe company served 40.9 thousand resupply patients, up approximately 22% year over year and 10.5% from the second quarter. PAP resupply orders increased 12% sequentially. Management is simplifying order processing to help patients receive supplies on time and support further participation in the resupply program.
- Maternal Health Expansion PlanEarly results from bringing maternal health services into established Viemed markets gave management confidence to expand the rollout. The company is on track to enter two additional states per quarter beginning in the fourth quarter, with a fulfillment partner established, network development underway, and reimbursement and state-level data being evaluated before launches.
- Improving Maternal Health Sales ExecutionManagement reported higher conversion rates from referral partners where sales representatives are active in the field. The company is combining technology, digital marketing, boots-on-the-ground sales resources, training, and fulfillment capabilities to increase maternal health volumes over time.
- Ventilation Revenue Growth Under New CMS RulesVentilator rental revenue increased from $35.4 million to $36.4 million and then $37 million across the first three quarters. First-nine-month ventilation revenue was approximately 8% above the same period last year, despite much of the 2025 comparison period preceding the new CMS coverage rules.
- Higher Adjusted EBITDA and Sequential Margin ExpansionAdjusted EBITDA was $17.1 million, up approximately 6% year over year and 24% sequentially. Adjusted EBITDA margin was 21.1%, compared with 17.6% in the second quarter and 22.4% a year ago, representing approximately 350 basis points of sequential margin expansion.
- Broad-Based Revenue GrowthRevenue increased 3.3% sequentially, with growth across rentals, equipment and supply sales, and services. Other equipment rentals grew approximately 13.1% year over year, while equipment and supply sales grew approximately 23.7%, supported by sleep and women's health.
- Supplier Capacity and Expected Cost SavingsA new distribution partner, together with existing suppliers, provides supplier capacity well beyond current needs across all product lines. Management expects related cost savings to improve gross margin by approximately 50 basis points once fully implemented.
- Strong Audit Outcomes and Compliance PositionManagement said its success rate under increased enforcement and claims audits remains very strong. The company believes its clinical care, documentation, personnel, and systems provide a competitive advantage as oversight increases across the DME industry.
- Cash Generation and Capital ReturnsOperating cash flow was $11.5 million and free cash flow was $4 million after $7.5 million of net capital expenditures. For the first nine months, operating cash flow was $35.5 million and free cash flow was $15.2 million; trailing-12-month free cash flow was approximately $26.1 million. Viemed repaid approximately $2.1 million of term debt, repurchased and canceled 115 thousand shares for approximately $1 million, and made an additional $2 million term-loan repayment in October.
- Improved Full-Year Revenue and Capital Expenditure OutlookThe company raised the lower end of its full-year revenue guidance to $316 million to $320 million from $314 million to $320 million. Net CapEx guidance was lowered to 8% to 9% of revenue from 8.5% to 10%, reflecting a greater contribution from less capital-intensive offerings.
- Fourth-Quarter Growth ExpectedManagement's revised outlook anticipates sequential growth in both revenue and adjusted EBITDA in the fourth quarter. Management also expects sleep resupply to show its best seasonality in the fourth quarter and expects ventilation active patients to increase sequentially based on current trends.
- Balance Sheet Provides Strategic FlexibilityAt September 30, cash was $9.7 million and borrowings under the credit facility were $5.3 million, with nothing drawn on the revolver. Management said the balance sheet provides flexibility to support maternal health and sleep growth, consider acquisitions that meet its requirements, and repurchase shares when valuation is attractive.
- Selective and Disciplined M&A StrategyManagement said the M&A pipeline is active and that it reviewed more than 40 deals last year but passed on them. Acquisition priorities remain home-based patient care, geographic expansion, payer expansion, and new service lines, while the company continues to emphasize organic growth.
VMD Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 10, 2027 | 2026 (Q4) | 0.16- | 0.14 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | 0.120.11 | 0.09 | 22.22% (+0.02) | |
| Aug 03, 2026 | 2026 (Q2) | 0.120.07 | 0.08 | -12.50% (-0.01) | |
| May 05, 2026 | 2026 (Q1) | 0.090.06 | 0.06 | 0.00% (+0.00) | |
| Mar 04, 2026 | 2025 (Q4) | 0.130.14 | 0.1 | 40.00% (+0.04) | |
| Nov 05, 2025 | 2025 (Q3) | 0.090.09 | 0.1 | -10.00% (-0.01) | |
| Nov 05, 2025 | 2026 (Q1) | 0.090.06 | 0.06 | 0.00% (+0.00) | |
| Aug 06, 2025 | 2025 (Q2) | 0.090.08 | 0.04 | 100.00% (+0.04) | |
| May 07, 2025 | 2025 (Q1) | 0.060.06 | 0.04 | 50.00% (+0.02) | |
| Mar 10, 2025 | 2024 (Q4) | 0.100.10 | 0.09 | 11.11% (+0.01) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


